DelveInsight’s “ER+/ HER2 -ve Breast Cancer Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the ER+/ HER2 -ve Breast Cancer market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).
The report covers emerging ER+/ HER2 -ve Breast Cancer drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current ER+/ HER2 -ve Breast Cancer treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
ER+/ HER2 -ve Breast Cancer: An Overview
ER+ (estrogen receptor-positive) and HER2- (human epidermal growth factor receptor 2-negative) breast cancer signifies a specific subtype of breast cancer characterized by the presence of estrogen receptors on the surface of cancer cells but an absence of HER2 protein overexpression. This subtype accounts for a significant proportion of breast cancer diagnoses. Symptoms of ER+/HER2- breast cancer are similar to other breast cancer types, such as a lump or thickening in the breast, changes in breast size or shape, nipple changes, or skin dimpling. Diagnosis involves a series of tests including mammograms, ultrasounds, MRIs, and biopsies to confirm the cancer type and stage.
Treatment for ER+/HER2- breast cancer often involves a multidisciplinary approach. Hormone therapies like tamoxifen or aromatase inhibitors are typically employed to target estrogen receptors, blocking their activity or reducing estrogen levels in the body. Surgery (lumpectomy or mastectomy), radiation therapy, and chemotherapy might be recommended based on the stage and aggressiveness of the cancer.
The burden of ER+/HER2- breast cancer is significant due to its prevalence and the necessity for long-term treatments, potentially leading to significant emotional, physical, and financial strains on patients and healthcare systems. Research continues to explore targeted therapies and personalized medicine approaches to improve treatment outcomes and reduce the burden on individuals affected by this breast cancer subtype. Early detection through screenings and advancing treatment options are critical in addressing the growing burden of ER+/HER2- breast cancer and improving survival rates.
ER+/ HER2 -ve Breast Cancer Market Key Facts
The total market size of ER+/HER2− Breast Cancer in the United States is USD 6,759 million in 2021 and is projected to grow during the forecast period (2022-2032).
The total market size of ER+/HER2− Breast Cancer in first-line settings in the United States is USD 3,471 million in 2021
The total incident population of Breast Cancer in the United States is 256,431 in 2021.
In the United States, more cases were observed for postmenopausal Breast Cancer, with 205,145 cases in 2021.
In 2021, cases of the localized, regional, distant, and unknown stages were observed to be 164,116, 74,365, 15,386, and 2,564 respectively. This number might increase during the forecast period.
Among the various subtypes of the disease (localized and regional), ER+/HER2− occupies the maximum patient pool, with 147,977 cases of this category, followed by the number of those with 24,325 cases of Triple-negative and 20,271 cases of ER+/HER2+. On the other hand, HR−/HER2+ accommodated the least number of cases.
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging ER+/ HER2 -ve Breast Cancer pipeline therapies. It also thoroughly assesses the ER+/ HER2 -ve Breast Cancer market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.
The report gives complete details of the market trend for each marketed ER+/ HER2 -ve Breast Cancer drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.
ER+/ HER2 -ve Breast Cancer Epidemiology Assessment
The epidemiology section provides insights into the historical, current, and forecasted ER+/ HER2 -ve Breast Cancer epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted ER+/ HER2 -ve Breast Cancer epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders.
The Report Covers the ER+/ HER2 -ve Breast Cancer Epidemiology, Segmented as –
Total incident population of Breast Cancer
Incidence of Breast Cancer cases by menopausal status
Stage-specific incidence of Breast Cancer
Subtype-specific incidence of Breast Cancer
Treatment eligible pool for localized and metastatic Breast Cancer
ER+/ HER2 -ve Breast Cancer Drugs Uptake and Pipeline Development Activities
The drug uptake section focuses on the uptake rate of potential drugs recently launched in the ER+/ HER2 -ve Breast Cancer market or expected to be launched during the study period. The analysis covers the ER+/ HER2 -ve Breast Cancer market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the market dynamics by drug sales, the most rapid drug uptake, and the reasons behind the maximal use of particular drugs. Additionally, it compares the ER+/ HER2 -ve Breast Cancer drugs based on their sale and market share.
The report also covers the ER+/ HER2 -ve Breast Cancer pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key ER+/ HER2 -ve Breast Cancer companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Learn How the ER+/ HER2 -ve Breast Cancer Market Will Evolve and Grow by 2032 @
ER+/ HER2 -ve Breast Cancer Therapeutics Analysis
Several major pharma and biotech companies are developing therapies for ER+/ HER2-VE Breast Cancer. Currently, Astrazeneca is leading the therapeutics market with its ER+/ HER2-VE Breast Cancer drug candidates in the most advanced stage of clinical development.
ER+/ HER2 -ve Breast Cancer Companies Actively Working in the Therapeutics Market Include
BeiGene, H3 Biomedicine, AstraZeneca, Olema Pharmaceuticals, CytomX Therapeutics, G1 Therapeutics, Sanofi, Jiangsu HengRui Medicine, Radius Pharmaceuticals, Sanofi, AstraZeneca, Eli Lilly, EQRx, Gilead, Sermonix Pharmaceuticals, Evgen Pharma, Tyme, Roche, Genentech, Daiichi Sankyo, Veru, and many others.
Emerging and Marketed ER+/ HER2 -ve Breast Cancer Therapies Covered in the Report Include:
IBRANCE (palbociclib): Pfizer
AFINITOR (everolimus): Novartis
Elacestrant: Radius Pharmaceuticals
Giredestrant (RG6171, GDC-9545): Roche
Camizestrant (AZD9833): AstraZeneca
LY3484356 (imlunestrant): Eli Lilly
Lerociclib (EQ132): EQRx
And Many Others
Download the Sample Report to Learn More About the Key Companies and Emerging Therapies @
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. ER+/ HER2 -ve Breast Cancer Competitive Intelligence Analysis
4. ER+/ HER2 -ve Breast Cancer Market Overview at a Glance
5. ER+/ HER2 -ve Breast Cancer Disease Background and Overview
6. ER+/ HER2 -ve Breast Cancer Patient Journey
7. ER+/ HER2 -ve Breast Cancer Patient Population and Epidemiology Trends (In the US, EU5, and Japan)
8. ER+/ HER2 -ve Breast Cancer Treatment Algorithm, Current Treatment, and Medical Practices
9. ER+/ HER2 -ve Breast Cancer Unmet Needs
10. Key Endpoints of ER+/ HER2 -ve Breast Cancer Treatment
11. ER+/ HER2 -ve Breast Cancer Marketed Therapies
12. ER+/ HER2 -ve Breast Cancer Emerging Drugs and Latest Therapeutic Advances
13. ER+/ HER2 -ve Breast Cancer Seven Major Market Analysis
14. Attribute Analysis
15. ER+/ HER2 -ve Breast Cancer Market Outlook (In US, EU5, and Japan)
16. ER+/ HER2 -ve Breast Cancer Companies Active in the Market
17. ER+/ HER2 -ve Breast Cancer Access and Reimbursement Overview
18. KOL Views on the ER+/ HER2 -ve Breast Cancer Market
19. ER+/ HER2 -ve Breast Cancer Market Drivers
20. ER+/ HER2 -ve Breast Cancer Market Barriers
22. DelveInsight Capabilities
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Request the Sample PDF to Learn More About the Key Offerings of the Report @
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Other Trending Healthcare Reports by DelveInsight
“Retinoblastoma Market Insights, Epidemiology, and Market Forecast-2032” report deliver an in-depth understanding of the historical and forecasted epidemiology as well as the Retinoblastoma market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the Retinoblastoma market.
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
Country: United States